인두염 치료제 시장 : 감염원별, 약제 클래스별, 유통 채널별, 지역별

Pharyngitis Therapeutics Market is estimated to be valued at USD 2.6 Bn in 2026 and is expected to reach USD 3.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.

The pharyngitis therapeutics market focuses on treating throat inflammation and infections. Healthcare providers prescribe antibiotics for confirmed bacterial cases and recommend analgesics, anti-inflammatory medicines, lozenges, and supportive therapies to relieve pain, fever, and swallowing difficulties. Increasing outpatient consultations for sore throat symptoms, broader diagnostic testing, and growing awareness of responsible antimicrobial use continue to influence demand for effective treatment options across hospitals, clinics, and primary healthcare settings.

Clinicians increasingly prioritize accurate diagnosis to distinguish bacterial pharyngitis from viral infections and select appropriate treatments. Rapid diagnostic tests help healthcare providers make faster treatment decisions and limit unnecessary antibiotic prescriptions. Pharmaceutical companies are also developing improved formulations that enhance symptom relief, convenience, and treatment adherence. Pediatric and adult respiratory infections, seasonal disease patterns, and demand for efficient outpatient care continue to support the need for effective pharyngitis therapies.

Market Dynamics

Respiratory infections continue to drive demand for pharyngitis therapeutics across primary care clinics, hospitals, and pharmacies. Healthcare providers increasingly use rapid diagnostic tests to differentiate bacterial infections from viral cases and determine suitable treatment. Greater awareness of antimicrobial stewardship also encourages clinicians to prescribe antibiotics selectively for confirmed bacterial infections. Meanwhile, patients continue to seek analgesics, anti-inflammatory medicines, throat lozenges, and supportive therapies to relieve throat pain, fever, and swallowing difficulties.

Diagnostic advancements create new opportunities by helping healthcare providers identify infection causes more quickly. Rapid antigen tests and molecular diagnostic technologies enable clinicians to make timely treatment decisions during initial consultations and avoid unnecessary treatment delays. Pharmaceutical companies are developing convenient formulations, combination therapies, and patient-friendly dosage forms to improve treatment adherence. Growing pediatric healthcare demand, seasonal infection patterns, and wider access to outpatient services further encourage healthcare providers to adopt effective and convenient pharyngitis treatment options.

The market faces challenges because viruses cause many pharyngitis cases, reducing the need for antibiotic therapy and increasing reliance on supportive care. Antimicrobial resistance further encourages clinicians to improve diagnosis and practice responsible antibiotic prescribing. Over-the-counter symptom-relief products also intensify competition among therapeutic alternatives. Despite these challenges, healthcare providers continue to prioritize efficient treatment pathways that combine accurate diagnosis, symptom management, and targeted therapy, creating opportunities for manufacturers that align their products with clinical requirements and antimicrobial stewardship.

Key Features of the Study

• It highlights potential revenue opportunities across various market segments and provides investment opportunity matrices for stakeholders involved in the Pharyngitis Therapeutics Market.
• This study offers key insights into market drivers, restraints, opportunities, treatment approaches, diagnostic advancements, pharmaceutical innovations, drug formulations, antimicrobial stewardship, disease patterns, regional outlook, and competitive strategies adopted by leading market participants.
• It profiles key players in the Pharyngitis Therapeutics Market based on company overview, product portfolio, recent developments, therapeutic innovations, research activities, strategic initiatives, and market positioning.
• Key companies covered as part of this study include Genentech Inc., Adamas Pharmaceutical Inc., PLIVA HRVATSKA d.o.o., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Mylan N.V., GSK group of companies, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.
• Insights from this report enable pharmaceutical companies, healthcare providers, investors, diagnostic companies, research organizations, distributors, and management teams to make informed decisions regarding drug development, treatment strategies, product launches, technology investments, market expansion, strategic collaborations, and therapeutic innovation.
• The Pharyngitis Therapeutics Market report serves a wide range of stakeholders, including investors, pharmaceutical manufacturers, biotechnology companies, healthcare providers, diagnostic companies, pharmacies, distributors, research organizations, technology developers, new market entrants, and financial analysts.
• Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, therapeutic assessment, treatment analysis, diagnostic evaluation, regional assessment, and market evaluation matrices presented in the Pharyngitis Therapeutics Market report.

Market Segmentation

• By Source of Infection (Revenue, USD Bn, 2021-2033)
  • Viral
  • Bacterial
• By Drug Class (Revenue, USD Bn, 2021-2033)
  • Antiviral Drugs
  • Antibacterial Drugs
  • Anti-inflammatory Drugs
  • Topical Anesthetics Drugs
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
  • Genentech Inc.
  • Adamas Pharmaceutical Inc.
  • PLIVA HRVATSKA d.o.o.
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Mylan N.V.
  • GSK group of companies
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Source of Infection
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Pharyngitis Therapeutics Market, By Source of Infection, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Viral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Bacterial
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Pharyngitis Therapeutics Market, By Drug Class, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Antiviral Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Antibacterial Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Anti-inflammatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Topical Anesthetics Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Pharyngitis Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Pharyngitis Therapeutics Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Source of Infection, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Genentech Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Adamas Pharmaceutical Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
  • Market Strategies
  • PLIVA HRVATSKA d.o.o.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Valeant Pharmaceuticals International, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • GSK group of companies
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us